First, we identified loss of the wild type copy via deletion or LOH in 10 out of 16 low stage HGS carcinomas with mutant TP53. Second, in the carcinomas without allelic loss of wild type TP53, expression analysis showed inactivation of the transcriptional activity of the wild type copy in our RNA sequence data for four more carcinomas. This evidence concerns the gene TP53 and carcinoma.